The Percentage of Anaplastic Lymphoma Kinase-Positive Tumor Cells Has Clinical Implications for Patients with Non-Small Cell Lung Cancer-Reference-Cited by-同舟云学术

The Percentage of Anaplastic Lymphoma Kinase-Positive Tumor Cells Has Clinical Implications for Patients with Non-Small Cell Lung Cancer

Published:2019-08 Issue:8 Volume:23 Page:589-597
ISSN:1945-0265
Container-title:Genetic Testing and Molecular Biomarkers
language:en
Short-container-title:Genetic Testing and Molecular Biomarkers

Author:

He Yuan¹²,Gong Rui¹²,Sun Li-Yue¹²,Zhang Zi-Chen²,Liu Xiao-Yun²,Shao Qiong²,Xu Fei¹²,Wang Hai-Yun¹²,Shao Jian-Yong¹²³

Affiliation:

1. State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Department of Molecular Diagnostics, Sun Yat-Sen University Cancer Center, Guangzhou, China.

2. Department of Molecular Diagnostics, Sun Yat-Sen University Cancer Center, Guangzhou, China.

3. School of Laboratory Medicine, Wannan Medical College, Wuhu, China.

Publisher

Mary Ann Liebert Inc

Subject

Genetics (clinical),General Medicine

Link

https://www.liebertpub.com/doi/pdf/10.1089/gtmb.2019.0038

Reference26 articles.

1. Correlations between the percentage of tumor cells showing an anaplastic lymphoma kinase (ALK) gene rearrangement,ALKsignal copy number, and response to crizotinib therapy inALKfluorescence in situ hybridization-positive nonsmall cell lung cancer

2. Serum Tumor Markers CEA, CYFRA21-1, and CA-125 Are Associated With Worse Prognosis In Advanced Non–Small-Cell Lung Cancer (NSCLC)

3. Targeted therapy for non-small-cell lung cancer: past, present and future

4. The function and therapeutic targeting of anaplastic lymphoma kinase (ALK) in non-small cell lung cancer (NSCLC)

5. MULTIVARIABLE PROGNOSTIC MODELS: ISSUES IN DEVELOPING MODELS, EVALUATING ASSUMPTIONS AND ADEQUACY, AND MEASURING AND REDUCING ERRORS

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Emerging Paradigms in Lung Cancer Treatment: Recent Breakthroughs and Innovation;Interdisciplinary Cancer Research;2024

2. The percentage of ALK-positive cells and the efficacy of first-line alectinib in advanced non-small cell lung cancer: is it a novel factor for stratification? (Turkish Oncology Group Study);Journal of Cancer Research and Clinical Oncology;2022-09-01

3. Crizotinib versus Alectinib for the Treatment of ALK-Positive Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis;Chemotherapy;2021-12-14

4. The association between thrombocytosis and subtype of lung cancer: a systematic review and meta-analysis;Translational Cancer Research;2021-03

5. The association between thrombocytosis and subtype of lung cancer: a systematic review and meta-analysis;2020-06-09